Inventor
GRANDEL ROLAND
DE23 patents
⚠️ This page may combine multiple inventors who share the name “GRANDEL ROLAND”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ABBOTT GMBH & CO KG
12 patentsUS6696437B1Feb 24, 2004
Heterocyclically substituted benzimidazoles, the production and application thereof
ABBOTT GMBH & CO KG92 citations97
USRE39608EMay 1, 2007
Substituted benzimidazoles and their use as PARP inhibitors
ABBOTT GMBH & CO KG30 citations92
US7041675B2May 9, 2006
Heterocyclic compounds and their use as PARP inhibitors
ABBOTT GMBH & CO KG22 citations92
US6737421B1May 18, 2004
Cyclo-alkyl substituted benzimidazoles and their use as PARP inhibitors
ABBOTT GMBH & CO KG37 citations90
US6919342B2Jul 19, 2005
Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ABBOTT GMBH & CO KG17 citations84
US7320979B2Jan 22, 2008
N-[(piperazinyl)hetaryl]arylsulfonamide compounds
ABBOTT GMBH & CO KG7 citations71
US7851463B2Dec 14, 2010
Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ABBOTT GMBH & CO KG2 citations61
US7834048B2Nov 16, 2010
Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ABBOTT GMBH & CO KG0 citations42
US7759397B2Jul 20, 2010
6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ABBOTT GMBH & CO KG0 citations42
US7026311B2Apr 11, 2006
Dibenzodiazepine derivatives, their preparation and use
ABBOTT GMBH & CO KG0 citations42
US8383641B2Feb 26, 2013
Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ABBOTT GMBH & CO KG0 citations41
US7994160B2Aug 9, 2011
Pyridazine compounds as glycogen synthase kinase 3 inhibitors
ABBOTT GMBH & CO KG0 citations38
DRESCHER KARLA
4 patentsUS8969552B2Mar 3, 2015
Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DRESCHER KARLA2 citations60
US8232426B2Jul 31, 2012
Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DRESCHER KARLA1 citations50
US8470810B2Jun 25, 2013
Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DRESCHER KARLA0 citations49
US8486984B2Jul 16, 2013
Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DRESCHER KARLA0 citations39
BASF AG
2 patentsBRAJE WILFRIED
2 patentsGRANDEL ROLAND
2 patentsUS8497273B2Jul 30, 2013
Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
GRANDEL ROLAND0 citations35
US8642642B2Feb 4, 2014
Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
GRANDEL ROLAND0 citations32